You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProLilly (Eli) (LLY)
22 stories published on LLY since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Lilly (Eli) (LLY) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
Eli Lilly to File Next-Generation Obesity Drug for Approval in Early 2027
Direct news · High influence · Long term
Eli Lilly's Obesity Drug Growth Turns Into a Global Story
Direct news · High influence · Long term
Medicare to Cover Obesity Drugs for the First Time, Opening a Major New Market for Eli Lilly's Zepbound
Direct news · High influence · Long term
Eli Lilly Stock: FDA Filing Delay for Next-Gen Weight-Loss Drug Retatrutide
Direct news · Medium influence · Short term
Eli Lilly Stock: Novo Nordisk Seeks Injunction Over Weight Loss Drug Ads
Direct news · Medium influence · Short term
Direct news
The most recent stories naming LLY directly, across all of our coverage.
Eli Lilly Stock: FDA Filing Delay for Next-Gen Weight-Loss Drug Retatrutide
Eli Lilly Stock: Novo Nordisk Seeks Injunction Over Weight Loss Drug Ads
Eli Lilly to File Next-Generation Obesity Drug for Approval in Early 2027
Novo Nordisk Initiates Legal Action Against Eli Lilly Over False GLP-1 Advertising
Eli Lilly Stock: LLY Adds Psychedelic Medicine With $2.8 Billion Deal
Eli Lilly Stock: Kisunla Alzheimer's Drug Studied With Once Yearly Dosing
Eli Lilly Stock: Foundayo Oral GLP-1 Scripts Rise as Weight-Loss Market Cools
Eli Lilly Stock: LLY to Buy AtaiBeckley for Up to $3.8 Billion in Psychedelic Drug Push
Eli Lilly Stock in Focus as LLY to Share New Kisunla and Alzheimer's Blood Test Data at AAIC
Tampa General Hospital Sues Eli Lilly Over 340B Discount Reporting Rules
Eli Lilly Stock in Focus as Oral GLP-1 Pill Foundayo's Launch Stays Muted
Eli Lilly's Obesity Drug Growth Turns Into a Global Story
FDA Receives Generic Applications for Lilly's Mounjaro and Zepbound
Medicare to Cover Obesity Drugs for the First Time, Opening a Major New Market for Eli Lilly's Zepbound
FDA Selects Eli Lilly and Regeneron for Manufacturing Facility Fast-Track Initiative
FDA Accepts Sandoz Generic Tirzepatide Application, Threatening Lilly's GLP-1 Franchise
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved LLY, with the stories behind each.
Also monitored for LLY (no news in our coverage yet): FDA approvals & trial outcomes, 10-Year Treasury yield.
See the full picture
Sign up free to track LLY, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track LLY for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.